An association was established between survivability and ATP7A expression, where high expression indicated poor survival in ovarian cancer patients treated with platinum-based chemotherapy, implying that increased ATP7A expression does confer a certain level of resistance to cisplatin-treated tumors [146]. The gene discussed is ATP7A; the disease is ovarian carcinoma.